Other examples of targeted (neo-) adjuvant therapy are the inhibition of vascular endothelial growth factor receptor (VEGFr) in patients with advanced colorectal cancer, the inhibition of HER2-Neu, an epidermal growth factor receptor in patients with breast cancer and the inhibition of both VEGFr and platelet-derived growth factor receptor (PDGFr) in patients with renal cell carcinoma (Hurwitz et al, 2004; Verweij et al, 2004; Geyer et al, 2006; Motzer et al, 2007). Here, KDR is linked to hereditary clear cell renal cell carcinoma.